Gastroenterology news and gastroenterology widget

POZEN Inc. (NASDAQ: POZN), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that, as part of the FDA's on-going discussions with the Company and their review of both the Special Protocol Assessment (SPA) for PA32540 and the Statistical Analysis Plan (SAP) for PN 400, the FDA is conducting an internal review on the acceptability of using endoscopic gastric ulcers as a primary endpoint in clinical studies.

A neuroscientist at UQ's Queensland Brain Institute has found a way to combat a debilitating illness that affects an estimated 50,000 people a year in tropical regions.